In the management of the childhood acute lymphoblastic leukemia (ALL), 5% of failures are due to induction death and treatment-related deaths in first complete remission. We retrospectively analyzed the incidence, pattern and causes of death and its risk factors for 896 children with ALL enrolled into five Austrian (A) Berlin-Frankfurt-Mü nster (BFM) trials between 1981 and 1999. The estimated 10-year cumulative incidence of death significantly decreased from 6 ± 1% (n ¼ 16/268) in trials ALL-BFM-A 81 and ALL-A 84 to 2 ± 1% (n ¼ 15/628) in trials ALL-BFM-A 86, 90 and 95 (P ¼ 0.006). A significant reduction of death was evident during induction therapy (2.2% in trials ALL-BFM-A 81 and ALL-A 84 and 0.2% in trials ALL-BFM-A 86, 90 and 95, P ¼ 0.001). Of 31 patients, 21 (68%) patients died from infectious and 10 (32%) from noninfectious complications. Treatment in trial ALL-BFM-A 81, infant age and female gender were independent predictors of an enhanced risk for death. Conclusively, we found a progressive reduction of death rates that may be explained by the increasing experience in specialized hemato-oncologic centers and improved supportive and intensive care. We also identified a distinct subset of patients who are especially prone to death and may need a special focus when receiving intense chemotherapy.
Introduction
Impressive advances in the management of childhood acute lymphoblastic leukemia (ALL) in recent decades have resulted in constantly increasing survival rates of children and adolescents with ALL. [1] [2] [3] With contemporary risk-adapted multiagent chemotherapy children with ALL have a chance of about 80% of long-term survival.
1,2,4 A major drawback of this anticancer success story is the fact that in most frontline multicenter trials on childhood ALL up to 5% of children die due to toxic side effects of antileukemic treatment. [5] [6] [7] [8] [9] [10] The majority of treatmentrelated deaths (TRD) occur during recurring and prolonged episodes of neutropenia and lymphopenia caused by cytotoxic and immunosuppressive drugs or by leukemia itself inhibiting bone marrow recovery during induction therapy, especially in slow-responding patients. In addition, several large cooperative study groups recently revealed that age, female gender, leukocyte count and constitutional trisomy 21 are risk factors for TRD and confirmed infections as the major cause of toxic death in children with ALL undergoing chemotherapy. 6, 7, 11, 12 Minor changes in chemotherapeutic treatment composition and scheduling have been repeatedly reported to have an impact on survival rates but also on treatment-related toxicity and mortality (TRM). 4, [13] [14] [15] [16] For instance, the substitution of prednisone by dexamethasone during induction chemotherapy as well as repeated and prolonged exposure to dexamethasone during maintenance therapy significantly increased the incidence of lethal infections as reported by Hurwitz et al. 9 Furthermore, using Escherichia coli L-asparaginase instead of Erwinia L-asparaginase not only proved to be more efficacious in ALL treatment but also to be associated with an unexpected mortality rate as reported from another trial. 10 These observations best reflect the struggle of balancing the risk for fatal treatment-related complications vs the benefit some treatment adjustments might have on cure of disease.
A distinct characterization of patients with an increased susceptibility to lethal infections or organ toxicity might allow providing more focused supportive care and thus minimizing the rate of induction death (ID) and TRM in first complete remission (CR). In the current study we retrospectively analyzed the incidence, pattern and causes of death as a first event as well as its risk factors (not related to refractory disease, relapsed disease and stem cell transplantation) for all children with ALL enrolled into five consecutive population-based Austrian (A) Berlin-Frankfurt-Mü nster (BFM) trials within the past 20 years (1981-1999).
Patients and methods
Between April 1981 and July 1999, 896 children and adolescents with ALL up to 21 years of age were diagnosed in Austria and all received frontline treatment according to the protocols ALL-BFM-Austria (A) 81 (n ¼ 141), ALL-A 84 (n ¼ 127), ALL-BFM-A 86 (n ¼ 142), ALL-BFM-A 90 (n ¼ 256) and ALL-BFM-A 95 (n ¼ 230). 1, 15, 17 Median follow-up was 11.68 years for patients included in trials ALL-BFM-A 81 and ALL-A 84 and 9.26 years for patients included in trials ALL-BFM-A 86, 90 and 95. Treatment stratification and protocols used in the respective trials have been published previously and response criteria as well as definition of relapse have been described in detail elsewhere. 1, 15, 17 All cases were reviewed by the national study center in Vienna and patients were treated according to the respective protocols after informed consent was obtained from the patients, patient's parents or legal guardians. 18 Studies were conducted in accordance with the Declaration of Helsinki Principles and approval was delivered by the relevant ethic committees.
Details on a patient's cause of death were collected from the central database at the national study center in Vienna and whenever necessary patient's charts were locally reviewed at the various participating study centers in Austria. Follow-up was updated at the end of 2006. Patients who died from initial disease complications before initiation of treatment, relapsed disease, secondary malignancy or complications after stem cell transplantation in first CR were excluded from the present analysis. All other children were categorized into three different subgroups with regard to their cause of death: (1) infection, (2) organ toxicity not related to an infection and (3) 'other causes'. Patients who died within the first 4-5 weeks after primary diagnosis of ALL (end of induction therapy) were defined as suffering from an ID. IDs were further subdivided by death within the first 2 weeks vs later deaths. Death in first CR included all children who died after having achieved CR. The following variables were evaluated as whether being risk factors for TRD: trial (period) the patients were enrolled into, age, gender, white blood cell (WBC) count at initial diagnosis, immunophenotype, evidence of Down's syndrome, initial central nervous system (CNS) disease status, prednisone response as evaluated by the number of blasts in peripheral blood after a 7-day pre-phase with prednisone and one intrathecal dose of methotrexate on day 1, treatment response in bone marrow after 2 weeks of chemotherapy (day 15), treatment response at the end of induction therapy (days 28-33), risk group allocation and genetic rearrangements.
Supportive care
Details of supportive care were outlined in the respective ALL protocols used and included measures for the management of hyperleukocytosis, bulky mediastinal mass, renal failure and prophylaxis, and treatment of tumor cell lysis syndrome. They further consisted of recommendations for prevention and treatment of Pneumocystis carinii pneumonia with cotrimoxazole, selective gut decontamination with nonabsorbable antibiotics and antimycotics, postexpositional Varicella-zoster virus prophylaxis, treatment of overt chickenpox and herpes zoster and guidelines for the substitution of blood products. Finally, protocols included some advice for continuous clinical observation during remission induction therapy, diagnostics during infectious complications, primary and secondary prophylaxis of fungal infections and empirical as well as targeted treatment of febrile neutropenia with broad-spectrum antibiotics and antimycotics. However, responsibility was always left at the discretion of the individual treatment center.
Statistical methods
Cumulative incidence (CI) functions of death as a first event were constructed by the method of Kalbfleisch and Prentice and were then compared by using Gray's test. In the calculation of the CI of death other failures such as progressive disease, relapsed disease and secondary malignancy were treated as competing events. The cumulative time to an event was defined as the time between date of ALL diagnosis and date of any event.
Patients surviving without any event were censored at the date of last follow-up. Patients who underwent stem cell transplantation in first CR were censored at the date of transplantation. Death rates were analyzed using the w 2 -test and multivariate risk factor analysis was performed according to the Cox regression model. The Cox regression analysis with step-wise variable selection was used to build a model for mortality with multiple risk factors. To allow for possible joint effects, all predictors were included as candidate variables, whether significant in univariate analysis. P-values p0.05 were referred to as statistically significant. The statistical analysis was carried out using the SAS statistical program (SAS-PC, version 9.1; SAS Institute Inc., Cary, NC, USA).
Results
Of the overall 896 patients analyzed 31 (3.4%) children with ALL died with all of them fulfilling the inclusion criteria of the present study for ID and TRM in first CR. They consisted 8 male and 23 female patients, presenting with a median age of 5.49 years (range 0.07-20.75 years) and a median WBC count of 7.1 Â 10 9 per liter (range 1.4-450.0 Â 10 9 per liter) at diagnosis. Detailed causes of death as well as exact time points of death within the protocols of the ALL trials are displayed in Tables 1, 2 and 3. In detail, the CI of death at a 10-year estimate was 9 ± 2% (n ¼ 13/141) in trial ALL-BFM-A 81, 2 ± 1% (n ¼ 3/127) in trial ALL-A 84, 4±2% (n ¼ 6/142) in trial ALL-BFM-A 86, 2±1% (n ¼ 4/256) in trial ALL-BFM-A 90 and 2 ± 1% (n ¼ 5/230) in trial ALL-BFM-A 95 (Po0.001). By comparing the earlier period of ALL trials in Austria (ALL-BFM-A 81, ALL-A 84) with the three following studies (ALL-BFM-A 86, 90 and 95) the CI of death significantly decreased from 6 ± 1% (n ¼ 16/268) to 2 ± 1% (n ¼ 15/628) (P ¼ 0.006).
A significant reduction of death rates was especially evident during induction therapy (overall 7/31 patients, 23%) with an ID rate of 2.2% (n ¼ 6/268) in trials ALL-BFM-A 81 and ALL-A 84 as compared to 0.2% (n ¼ 1/628) in trials ALL-BFM-A 86, 90 and 95 (P ¼ 0.001). In detail, four out of the seven patients died from infection including three patients with a proven septicemia (Streptococcus viridans, Staphylococcus aureus, Candida not specified) and one patient with a septic shock with presumed bacterial infection. Of the remaining three patients two suffered from acute fatal myocardial complications and one case was assigned to the group of 'other causes' with a multiorgan failure (MOV) due to a presumed inherited metabolic disorder. In the period of trials ALL-BFM-A 86, 90 and 95 no patient died up to day 15 of induction chemotherapy whereas in the two earlier trials four of six children died within the first 2 weeks of chemotherapy.
Of the 31 patients studied, 24 (77%) died after having achieved first CR including 17 (71%) cases with a fatal infectious complication and seven (29%) with a TRD other than infection. Of 24 patients, 22 (92%) died during therapy and 2 children (8%) died after completion of all planned therapy. There was no significant reduction of TRD in first CR when comparing trials ALL-BFM-A 81 and ALL-A 84 (n ¼ 10/268, 3.7%) with the following trials ALL-BFM-A 86, 90 and 95 (n ¼ 14/628, 2.2%; P ¼ 0.202).
In the analysis of the whole study group of 31 patients, 21 (68%) patients died from an infection and 10 (32%) patients from noninfectious organ complications or 'other causes'. Infectious death rates increased from 63% (n ¼ 10/16) in trials ALL-BFM-A 81 and ALL-A 84 to 73% (n ¼ 11/15) in trials ALL-BFM-A 86, 90 and 95 whereas noninfectious death rates decreased from 37% (n ¼ 6/16) to 27% (n ¼ 4/15) (P ¼ 0.519). Out of the 21 fatal infectious complications, 4 (19%) suffered from a proven bacterial infection, 3 (14%) from an invasive fungal infection, another 3 (14%) from P. carinii pneumonia (proven, n ¼ 1; clinically suspected, n ¼ 2) and 2 (10%) children Toxic deaths in Austrian ALL-BFM trials C Prucker et al died from a cytomegalovirus (CMV) infection. Of the remaining nine patients (43%) four died from a septic shock presumed from bacterial infection and another five succumbed to pneumonia without an infectious agent identified.
Noninfectious causes of death occurred in 10/31 (32%) patients including fatal cardiomyopathy in 3 (acute, n ¼ 2; chronic, n ¼ 1) and fatal encephalopathy in further 3 patients (unknown origin, n ¼ 2; possible association with methotrexate, n ¼ 1). Four patients were assigned to the group of 'other causes' (mesenterial thrombosis, n ¼ 1; MOV, n ¼ 1; brain hemorrhage, n ¼ 1 and anorexia nervosa, n ¼ 1).
Univariate analysis demonstrated that study period (P ¼ 0.006), age o1 year and X10 years (P ¼ 0.006), and female gender (Po0.001) were significantly associated with a higher risk of death (Table 4) . However, other parameters at initial diagnosis such as WBC count, immunophenotype and CNS disease status did not carry a different risk for death (Table 4) . Also, the presence of a constitutional trisomy 21, risk group allocation and parameters of early response assessment in peripheral blood and bone marrow were not associated with an increased risk for death. Moreover, the presence of genetic rearrangements (available in all patients from trial ALL-BFM-A 86 onwards) such as the classic ETV6/RUNX1, TCF3/PBX1, MLL/AF4 and BCR/ABL1 translocations did not have an impact on death.
In multivariate analysis, age o1 year (P ¼ 0.022; hazard ratio: 4.202), female gender (P ¼ 0.002; hazard ratio: 3.484) and treatment within trial ALL-BFM-A 81 (P ¼ 0.006; hazard ratio: 4.292) were significantly associated with a higher incidence of death.
Discussion
Despite the continuous intensification of antileukemic chemotherapeutic regimens, rates of ID and TRM in first CR have concomitantly decreased, hence accounting for only a small proportion of failures in the management of children and adolescents with ALL. 1, 6, 7, 19 However, as compared to the past two decades when pediatric oncologists were mainly focused on reducing the number of relapses, currently, in sight of increasing overall survival rates to more than 80%, avoidance of treatment-related fatalities as a first event is a major aim in the optimal management of childhood ALL. In particular, it is conceivable that a number of patients, who would be otherwise cured, die from treatment-related causes, which, if avoidable, could further increase survival rates.
Out of the 896 patients with ALL enrolled into five consecutive Austrian multicenter trials (ALL-BFM-A 81, ALL-A 84, ALL-BFM-A 86, 90, 95) 31 (3.4%) died during remission induction therapy (n ¼ 7) and due to treatment-related toxicity in first CR (n ¼ 24). Notably, the CI of death at a 10-year estimate significantly decreased from 6±1% in trials ALL-BFM-A 81 and ALL-A 84 to 2 ± 1% in trials ALL-BFM-A 86, 90 and 95. More than halving the risk of mortality over a period of 20 years may be due to the facts that specialized centers had gained skills and experience on performing intensive chemotherapy and dealing with severe treatment complications and that the tools for antiinfectious and hematological supportive and intensive care have concomitantly improved. Other explanations for the significant reduction of death rates during induction therapy from trials ALL-BFM-A 81 and ALL-A 84 to trials ALL-BFM-A 86, 90 and 95 are difficult to find but may be due to the implementation of a mandatory initial 7-day cytoreductive pre-phase with prednisone in 1986, and the reduction of the anthracycline dose for standard-risk patients and of the L-asparaginase dose for all patients in trial ALL-BFM-A 95.
1,15
The core ALL-BFM study group comprising children and adolescents with ALL from Austria and most parts of Germany and Switzerland has not yet published detailed data concerning death rates over the time of its large studies but has usually included them in its reports of the overall trial results. For instance, Schrappe et al. 19 and Mö ricke et al. 1 reported ID rates of 1.0 and 0.7% in trials ALL-BFM 90 (n ¼ 2178) and ALL-BFM 95 (n ¼ 2169), and death rates of 1.6 and 2.1%, respectively, in first CR. Expectedly, their findings are in the range of the results of the trial subpopulation from Austria presented herein with 10 times fewer numbers of patients diagnosed per year as compared to Germany.
Similar achievements in reduction of death rates have been observed in several other multicenter trials on childhood ALL. The Medical Research Council (MRC) reported on a significant decline in the percentage of mortality rates as it fell from 9% in trial MRC United Kingdom ALL (MRC UKALL) VIII to 2% in trial MRC UKALL XI, reflecting a time frame of nearly 20 years Pneumonia without an identified infectious agent 5 Toxic deaths in Austrian ALL-BFM trials C Prucker et al (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) and attributed to a significant decrease in infections with P. carinii and measles. 6 Although not statistically significant, the Dutch Childhood Oncology Group also found a decline in early death (ED) frequencies and chemotherapyrelated mortality (CRM) in first CR from trial ALL-96 (ED 1.1%, CRM 1.6%) to trial ALL-98 (ED 0.4%, CRM 0.7%). 12 Moreover, the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-92 trial, which was carried out between 1992 and 2001 and included 1652 patients, found a 3% death rate during induction therapy (1%) and in first CR (2%). 11 Finally, a report of the St Jude Children's Research Hospital (SJCRH) showed that the CI of death at a 10-year estimate decreased from 3.1 ± 0.9% in Total Therapy Study XI to 2.5 ± 1.0% in Total Therapy Study XIIIB. 7 Approximately two-thirds of deaths (n ¼ 21/31, 68%) in the present study were caused by infections, with an identified pathogen in 10 cases. In half of the cases the infectious agent could not be exactly defined, stressing the importance of refined sensitive and specific diagnostic (microbiological) tools that might enable a more targeted therapy with a higher efficacy and lesser side effects that usually emerge from empirical and multimodal therapy. The high proportion of deaths due to infections has been reported by others as well. 6, 7, 11, 12 In the present analysis, fatal bacterial septicemia was common during induction therapy (5/7 patients with ID) whereas all three fatal fungal infections occurred after having achieved first CR. This was somehow different in the Total Therapy Studies of the SJCRH in which deaths because of invasive fungal infections accounted for 8 of 11 infectious deaths during induction therapy. 7 Recently, the ALL-BFM study group also reported that fungal pathogens were responsible for up to one-fifth of all infectious deaths in children enrolled in trial ALL-BFM 95, however, all of them occurring after having achieved first CR. 20 Viral infections caused by CMV after cessation of oral maintenance therapy and fatal P. carinii pneumonia occurred in two and three patients, respectively. Two of the latter three cases of death are especially tragic as they happened due to suspected incompliance in a time in which routine prophylaxis with oral cotrimoxazole was already established. Importantly, the decline of TRM within the MRC UKALL trials was largely due to a significant reduction of P. carinii pneumonia during maintenance therapy.
6 Table 3 Causes and time point of induction death and TRD in first CR within the protocols of the Austrian ALL-BFM trials The number of deaths during remission induction therapy of the earlier trials ALL-BFM-A 81 and ALL-A 84 is consistent with the observation that especially 3-4 weeks after initiation of a four-drug induction therapy (corticosteroids, vincristine, L-asparaginase and daunorubicine) immunosuppression and persistent neutropenia are most severe. Thus, it is remarkably reassuring that especially ID rates have been significantly fallen from 2.2% in trials ALL-BFM-A 81 and ALL-A 84 to 0.2% in trials ALL-BFM-A 86, 90 and 95. This may again be explained by improved intensive and supportive care and accumulating experience of treating centers. Number of agents (three or four drugs) and type of corticosteroids (prednisone or dexamethasone) used in remission induction therapy are currently a matter of debate in almost all collaborative study groups. On the one hand, specific ALL subgroups significantly benefit from the addition of an anthracycline and/or use of dexamethasone whereas on the other hand several reports have found a significantly increased risk of ID when using additional daunorubicine (MRC UKALL VIII) and/or substituting dexamethasone for prednisone in induction therapy. 9, [21] [22] [23] [24] [25] [26] [27] In multivariate risk factor analysis, we showed that children enrolled into trial ALL-BFM-A 81, infants as well as female patients had a significantly enhanced risk for death. Similar findings concerning the relevance of age or gender have been reported by others. Within the Total Therapy Studies of the SJCRH children X10 years of age had the greatest risk of death and in trial MRC UKALL XI older age also proved as a significant risk factor. 6, 7 The biological mechanisms behind the findings that age and female sex have an impact on a patient's risk for death are not elucidated but may reflect age-and gender-dependent differences in immunological response mechanisms to infections and pharmacokinetics following cytotoxic chemotherapy. 28 In contrast to our results, both the SJCRH and the MRC also found high WBC counts at diagnosis to be significantly associated with an enhanced risk of mortality. 6, 7 In particular, the British study showed that this was preferentially true for death during remission induction therapy and associated with patients dying from cerebral hemorrhage.
In line with the increased risk of death in female patients seen in the present study, the NOPHO ALL-92 trial confirmed that girls had a higher risk of death. 11 Moreover, the NOPHO and MRC UKALL trials also found a significantly enhanced risk of death in ALL patients with Down's syndrome, a finding that may be explained by the patients' relative immune deficiency, cardiopulmonary comorbidities and higher toxicity when receiving (high dosages of) methotrexate. 6, 11, 29, 30 However, the presence of Down's syndrome was not associated with a higher risk of mortality within our study population.
In summary, we have shown that ID and TRD in first CR have favorably declined from the earlier era of ALL-BFM trials in Austria to the more recent era reflecting the increasing experience of specialized centers and pediatric physicians, continuous basic and advanced training as well as improvements in supportive and intensive care. In addition, we revealed infant age and female gender as independent risk factors for death as a first event and could thus define a subset of patients who are especially prone to suffer from treatment-related toxicity and may need a special vigilance when receiving intense chemotherapy.
